Has Harry Moore, MD received payments from drug or device companies?

Yes. Drug and device makers reported $20,168 in general payments to Harry Moore, MD across 938 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Harry Moore, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Harry Moore, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Harry Moore, MD

Medical Oncology · Macon, GANPI 1699096388

Payments from drug & device makers

$20,168in general payments, 2019–2025

Across 938 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2K
Merck$1K
Pfizer$914
AstraZeneca$814
AbbVie$799
Astellas Pharma US Inc$749
plus $13K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	69	$2,419
Merck	61	$1,130
Pfizer	58	$914
AstraZeneca(2 entities)	48	$814
AbbVie	35	$799
Astellas Pharma US Inc	40	$749
Regeneron Healthcare Solutions, Inc.	26	$731
Daiichi Sankyo Inc.	31	$721
Genentech USA, Inc.	36	$694
Johnson & Johnson(2 entities)	35	$661
Gilead(2 entities)	35	$656
Incyte Corporation	27	$654
Exelixis Inc.	27	$652
Amgen	37	$641
Bayer	30	$593
Seagen Inc.	30	$586
Sanofi	22	$536
Pharmacyclics LLC, An Abbvie Company	17	$472
Takeda Pharmaceuticals U.S.A., Inc.	13	$321
Eisai Inc.	17	$313
Myriad Genetic Laboratories, Inc.	5	$268
Bristol Myers Squibb	15	$268
Global Blood Therapeutics, Inc.	2	$262
AVEO Pharmaceuticals, Inc.	12	$251
E.r. Squibb & Sons, L.L.C.	12	$224
Coherus Oncology, Inc.	13	$217
Jazz Pharmaceuticals Inc.	9	$217
GSK	12	$211
Stemline Therapeutics Inc.	8	$197
Blueprint Medicines Corporation	9	$181
Servier Pharmaceuticals LLC	10	$178
Beigene USA, Inc.	10	$173
Lilly USA, LLC	9	$160
Ipsen Biopharmaceuticals, Inc	8	$146
Adaptive Biotechnologies Corporation	7	$137
Array Biopharma Inc	10	$134
Karyopharm Therapeutics Inc.	6	$125
Clovis Oncology, Inc.	5	$124
Sobi, Inc	5	$116
Puma Biotechnology, Inc.	6	$106
Epizyme, Inc.	6	$104
Rigel Pharmaceuticals, Inc.	5	$101
Syndax Pharmaceuticals, Inc.	4	$95
Tesaro, Inc.	5	$86
Boehringer Ingelheim	3	$72
Sun Pharmaceutical Industries Inc.	2	$63
Geron Corporation	3	$61
Tersera Therapeutics LLC	3	$61
Medtronic	2	$57
Agios Pharmaceuticals, Inc.	3	$54
Pharmacosmos Therapeutics Inc.	3	$51
Mirati Therapeutics, Inc.	3	$46
Beone Medicines USA, Inc.	2	$45
AMAG Pharmaceuticals, Inc.	2	$38
Verastem, Inc.	2	$35
Heron Therapeutics, Inc.	2	$34
Morphosys, US Inc.	2	$34
Tolmar, Inc.	1	$33
Pharmaand GmbH	1	$33
Iovance Biotherapeutics, Inc.	1	$32

How this compares

$20,168 in reported general payments places this provider in the 45th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Medicare billing

Part B allowed, 2024

$7,879,922

Medicare patients

1,601

Services billed

332,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Macon

Bradley SumrallMacon$246K
Suresh RamalingamAtlanta$10.5M
Jonathan KaufmanAtlanta$7.7M
Samir KhleifAugusta$5.6M
Badi El OstaDecatur$3.5M
Nabil SabaAtlanta$2.8M
Olumide GbolahanAtlanta$2.7M
Bradley CarthonAtlanta$2.7M
Amelia LangstonAtlanta$2.1M
Ragini KudchadkarAtlanta$2M

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →